The objectives of this grant, which has been funded for almost 35 years, have been to understand the mechanisms for the establishment and alteration of the human epigenome in cancer by focusing on DNA methylation patterns. We also strive to understand how drugs such as 5-aza-2'-deoxycytidine (5-aza-CdR) interfere with cytosine methylation and reactivate silenced genes. This research has led to the approval by the FDA of two DNA demethylating agents (5-aza-CR and 5-aza-CdR) for the treatment of myelodysplastic syndrome (MDS) and we have been successful over the last five years in the preclinical development of the first next-generation nucleoside inhibitor of DNA methylation called SGI110. This drug has been undergoing Phase I/II testing and shows great promise. In the next five year period of the project, we hope to take advantage of an innovative new technique we have developed called NOMe-seq which allows us to simultaneously map nucleosomes and DNA methylation patterns either at the level of individual DNA molecules (i.e., replicas of individual transcription start sites, etc.), or genome-wide. By coupling this technique with ChIP-seq and RNA expression analysis and next-generation sequencing, we gain a holistic view of the human epigenome and how it is altered in cancer for the first time.
In Specific Aim 1, we will use this approach to define how DNA methylation acts genome-wide to position nucleosomes at regulatory regions and throughout the genome. We will then explore the mechanisms by which chromatin remodelers and histone methyltransferases alter the epigenome. This is crucial because a large number of mutations in chromatin modifiers have been discovered over the past five years, but we know little about the potential effects of these mutations on the epigenome.
In Specific Aim 2, we investigate how perturbing DNA methylation with 5-aza- CdR alters the entire epigenome and the expression of subsets of genes. We are particularly interested in exploring the time course by which different sets of genes become activated and then become resilenced as a function of time after treatment. A novel part of this Aim will be to investigate the effect of gene body methylation on transcriptional elongation which may, unexpectedly, play a role in the patient's response to these drugs.
In Specific Aim 3, we plan a first epigenome-wide analysis of uncultured human tumors by focusing on colon tumors and adjacent tissue. The completion of these Specific Aims will give us a better understanding of why and how the epigenome is altered in cancer, how it responds to drugs and hopefully will result in better treatments for patients.

Public Health Relevance

This grant will show, in a holistic way, how the epigenome is modified in cancer, help explain how mutations alter the structure of the epigenome, measure the response of the epigenome to demethylation inhibitors and provide the first comprehensive integrated view of chromatin in uncultured human cancers. It has profound implications for the future development of epigenetic therapies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA082422-16
Application #
8692362
Study Section
Cancer Genetics Study Section (CG)
Program Officer
Okano, Paul
Project Start
1999-09-17
Project End
2019-07-31
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
16
Fiscal Year
2014
Total Cost
$525,399
Indirect Cost
$221,558
Name
Van Andel Research Institute
Department
Type
DUNS #
129273160
City
Grand Rapids
State
MI
Country
United States
Zip Code
49503
Becket, Elinne; Chopra, Sameer; Duymich, Christopher E et al. (2016) Identification of DNA Methylation-Independent Epigenetic Events Underlying Clear Cell Renal Cell Carcinoma. Cancer Res 76:1954-64
Baylin, Stephen B; Jones, Peter A (2016) Epigenetic Determinants of Cancer. Cold Spring Harb Perspect Biol 8:
Duymich, Christopher E; Charlet, Jessica; Yang, Xiaojing et al. (2016) DNMT3B isoforms without catalytic activity stimulate gene body methylation as accessory proteins in somatic cells. Nat Commun 7:11453
Liu, Minmin; Ohtani, Hitoshi; Zhou, Wanding et al. (2016) Vitamin C increases viral mimicry induced by 5-aza-2'-deoxycytidine. Proc Natl Acad Sci U S A 113:10238-44
Charlet, Jessica; Duymich, Christopher E; Lay, Fides D et al. (2016) Bivalent Regions of Cytosine Methylation and H3K27 Acetylation Suggest an Active Role for DNA Methylation at Enhancers. Mol Cell 62:422-31
Statham, Aaron L; Taberlay, Phillippa C; Kelly, Theresa K et al. (2015) Genome-wide nucleosome occupancy and DNA methylation profiling of four human cell lines. Genom Data 3:94-6
Lay, Fides D; Liu, Yaping; Kelly, Theresa K et al. (2015) The role of DNA methylation in directing the functional organization of the cancer epigenome. Genome Res 25:467-77
Roulois, David; Loo Yau, Helen; Singhania, Rajat et al. (2015) DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts. Cell 162:961-73
Jeong, Kwang Won; Andreu-Vieyra, Claudia; You, Jueng Soo et al. (2014) Establishment of active chromatin structure at enhancer elements by mixed-lineage leukemia 1 to initiate estrogen-dependent gene expression. Nucleic Acids Res 42:2245-56
Yang, Xiaojing; Han, Han; De Carvalho, Daniel D et al. (2014) Gene body methylation can alter gene expression and is a therapeutic target in cancer. Cancer Cell 26:577-90

Showing the most recent 10 out of 54 publications